Company Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients.
Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy.
In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs.
Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
| Country | United Kingdom |
| Founded | 2020 |
| IPO Date | May 28, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Saurabh Saha |
Contact Details
Address: 1 Ashley Road, 3rd Floor Altrincham, WA14 2DT United Kingdom | |
| Website | centessa.com |
Stock Details
| Ticker Symbol | CNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001847903 |
| CUSIP Number | 152309100 |
| ISIN Number | US1523091007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Saurabh Saha M.D., Ph.D. | Chief Executive Officer and Director |
| Dr. David M. Chao Ph.D. | Chief Administrative Officer |
| John J. Crowley CPA | Chief Financial Officer and Principal Financial and Accounting Officer |
| Tia L. Bush | Chief Technology and Quality Officer |
| Kristen K. Sheppard Esq., J.D. | Senior Vice President of Investor Relations and Corporate Communications |
| Iqbal J. Hussain L.L.B. | General Counsel, Chief Compliance Officer and Corporate Secretary |
| Karen M. Anderson | Chief People Officer |
| Dr. Gregory M. Weinhoff M.B.A., M.D. | Chief Business Officer |
| Dr. Mario Alberto Accardi Ph.D. | President of the Orexin Program |
| Dr. Ellie Im M.D. | Senior Vice President of Clinical Development and Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 21, 2025 | 144 | Filing |
| Jan 15, 2025 | 144 | Filing |
| Jan 8, 2025 | 8-K | Current Report |
| Dec 30, 2024 | 8-K | Current Report |
| Dec 26, 2024 | 144 | Filing |
| Dec 20, 2024 | 144 | Filing |
| Dec 17, 2024 | 144 | Filing |
| Dec 16, 2024 | 144 | Filing |
| Dec 16, 2024 | 144 | Filing |
| Dec 13, 2024 | 144 | Filing |